We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Cardiology

Journal Scan / Research · April 15, 2016

Individualized ACE-Inhibitor Therapy in Patients With Stable CAD Based on Clinical and Pharmacogenetic Determinants

Journal of the American Heart Association


Additional Info

Journal of the American Heart Association
Individualized Angiotensin-Converting Enzyme (ACE)-Inhibitor Therapy in Stable Coronary Artery Disease Based on Clinical and Pharmacogenetic Determinants: The PERindopril GENEtic (PERGENE) Risk Model
J Am Heart Assoc 2016 Apr 01;5(3)e002688, RM Oemrawsingh, KM Akkerhuis, LC Van Vark, WK Redekop, G Rudez, WJ Remme, ME Bertrand, KM Fox, R Ferrari, AH Danser, M de Maat, ML Simoons, JJ Brugts, E Boersma

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading